Insider · CIK 0001890563
Michael Nohaile
Files at FLGT (Fulgent Genetics, Inc.). First filing -, latest -.
Michael Nohaile files SEC Form 4 as director at FLGT (Fulgent Genetics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Michael Nohaile has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | FLGT Fulgent Genetics, Inc. | AGrant or award Common Stock | +5,558 | $0.00 | $0 | 24,578 | May 18, 2026 |
| May 14, 2026 | FLGT Fulgent Genetics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +8,426 | $0.00 | $0 | 8,426 | May 18, 2026 |
| May 15, 2025 | FLGT Fulgent Genetics, Inc. | AGrant or award Common Stock | +4,491 | $0.00 | $0 | 19,020 | May 19, 2025 |
| May 15, 2025 | FLGT Fulgent Genetics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +6,311 | $0.00 | $0 | 6,311 | May 19, 2025 |
Questions about Michael Nohaile
Answered from the filings on this page, as of the latest one.
Is Michael Nohaile buying or selling?
Michael Nohaile has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Michael Nohaile's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael Nohaile has 0.
Where does Michael Nohaile file Form 4?
Michael Nohaile has filed Form 4 at FLGT (Fulgent Genetics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.